Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of NS-87 in Japanese adults with high-risk acute myeloid leukemia
jRCT2080224810Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jul 2019
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of daunorubicin and cytarabine in acute myeloid leukemia (AML), leukemia (therapy-related acute myeloid) (t-AML) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), sponsored by Nippon Shinyaku. Started Jul 2019; status: completed.
02
Drugs
daunorubicin and cytarabine
03
Conditions
acute myeloid leukemia (AML)leukemia (therapy-related acute myeloid) (t-AML)acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)
Beyond the preview
Go deeper on jRCT2080224810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224810.